Dysport makes migraine history with a double win in Phase 3 trials. AbobotulinumtoxinA (Dysport) became the first botulinum toxin to show statistically significant efficacy in preventing both episodic and chronic migraine, hitting primary endpoints in the E-BEOND and C-BEOND trials. If approved, it could open a new preventive treatment avenue for the roughly 1.16 billion people worldwide living with migraine.
Dysport makes migraine history with a double win in Phase 3 trials
Ipsen's abobotulinumtoxinA (Dysport) just cleared a major milestone: it's the first botulinum toxin ever to demonstrate statistically significant efficacy in preventing both episodic and chronic migraine. The results come from the BEOND Phase 3 program, which included two randomized, placebo-controlled trials — E-BEOND (episodic migraine) and C-BEOND (chronic migraine) — enrolling 1,510 adults across 120 centers globally. Both trials met their shared primary endpoint: a significant reduction in monthly migraine days at week 24 compared to placebo.
The drug was well-tolerated with no new or unexpected safety signals, consistent with its long-established profile across ~90 countries and over 21 million treatment-years of use. An open-label extension phase is ongoing through week 48, with full long-term data still pending.
By the Numbers
Why it matters: Preventive options for episodic migraine — the more common form — are notably limited. A botulinum toxin approval in this space could meaningfully expand the treatment toolkit for a massive, underserved patient population.
